Clearside Biomedical, Inc. (NASDAQ:CLSD) Q4 2023 Earnings Call Transcript
Operator: Greetings, and welcome to the Clearside Biomedical Q4 2023 Financial Results and Corporate Update Call. At this time, all participants are in a listen-only mode.
Clearside Biomedical Inc. (CLSD)
Market is closed
Sector: Pharmaceutical Preparations
Hedge Fund Popularity
Hedge Fund Holdings
Filing Period:
Last updated on based on SEC 13F filings Last update:
| No. | Hedge Fund | Shares | Value | Activity | % Port |
|---|---|---|---|---|---|
| 1. | Citadel Investment Group Ken Griffin | 45,838 | $53,630 | +133% | 0% |
| 2. | Millennium Management Israel Englander | 33,638 | $39,356 | 0% | |
| 3. | 9,600 | $11,232 | -18% | 0% | |
| 4. | 8,500 | $9,945 | 0% | ||
| 5. | Renaissance Technologies Jim Simons | 384,689 | $450,000 | +41% | 0% |
Insider Trading: Purchases See All
| Insider | Price | Amount | Relationship | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $1.30 | 93,290 | 100,000 | 2024-04-18 | Filing | ||
| $1.25 | 6,710 | 6,710 | 2024-04-17 | Filing | ||
| $1.60 | 30,000 | 30,000 | 2024-03-20 | Filing | ||
| $1.35 | 444,444 | Large Shareholder | 4,495,034 | 2024-02-07 | Filing | |
| $0.74 | 64,366 | Large Shareholder | 4,050,590 | 2023-11-01 | Filing |
Insider Trading: Sales See All
| Insider | Price | Amount | Relationship | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $1.27 | 18,000 | Officer, Director | 466,577 | 2024-01-19 | Filing | |
| $1.28 | 12,900 | Officer | 384,662 | 2024-01-19 | Filing | |
| $1.47 | 13,700 | Officer | 291,890 | 2023-01-20 | Filing | |
| $1.46 | 20,030 | Officer, Director | 484,577 | 2023-01-19 | Filing | |
| $1.50 | 14,030 | Officer | 363,472 | 2023-01-19 | Filing |
Institutional Investors' Holdings
Filing Period:
| No. | Name | Shares | Value | % Port |
|---|---|---|---|---|
| 1. | 2,176,316 | $2,546,290 | 0% | |
| 2. | 2,132,744 | $2,495,310 | 0.04% | |
| 3. | 759,743 | $888,900 | 0% | |
| 4. | 490,690 | $574,256 | 0% | |
| 5. | 193,363 | $226,235 | 0% |
News See All
Clearside Biomedical, Inc. (NASDAQ:CLSD) Q3 2023 Earnings Call Transcript
Operator: Greetings, and welcome to the Clearside Biomedical Third Quarter 2023 Financial Results and Corporate Update Call.
Clearside Biomedical, Inc. (NASDAQ:CLSD) Q1 2023 Earnings Call Transcript
Operator: Good day and thank you for standing by. Welcome to the Clearside Biomedical First Quarter 2023 Financial Results and Corporate Update Call.
Clearside Biomedical, Inc. (NASDAQ:CLSD) Q4 2022 Earnings Call Transcript
Operator: Good day and thank you for standing by and welcome to the Clearside Biomedical Fourth Quarter 2022 Financial Results and Corporate Update Conference Call.
Clearside Biomedical, Inc. (CLSD): Hedge Funds Are Snapping Up
Most investors tend to think that hedge funds and other asset managers are worthless, as they cannot beat even simple index fund portfolios.
Here is What Hedge Funds Think About Clearside Biomedical, Inc. (CLSD)
At the end of February we announced the arrival of the first US recession since 2009 and we predicted that the market will decline by at least 20% in (Recession is Imminent: We Need A Travel Ban NOW).
Hedge Funds Warming Up To Clearside Biomedical, Inc. (CLSD) Again?
Insider Monkey has processed numerous 13F filings of hedge funds and successful value investors to create an extensive database of hedge fund holdings.
Major Stock Movers: Inuvo, Clearside Biomedical, Cirrus Logic, and More
It's Monday and oil futures are relatively stable despite the news that the U.S. is beginning to impose sanctions on Iran again. Among the stocks making substantial waves today include Inuvo Inc.
This Biotech Investor's Picks Returned 31% in Q1; Here Are Its New Bets
Peter Kolchinsky is one of the best biotech investors and many of his stock picks generate strong returns.
Market Movers Today: Dermira Inc (DERM), Intrepid Potash, Inc. (IPI), XL Group Ltd (XL), Sparton Corporation (SPA), and More
In a major surprise for Dermira Inc. and Wall Street alike, Dermira’s acne drug failed to meet the co-primary endpoints of two important, late-stage clinical trials.